Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Inclusion criteria: * Documented Complete Response, Partial Response, or Stable Disease at the time of entry to extension study and/or possible benefit from continuing treatment in the view of the investigator. * Normal organ and marrow function as defined in core protocol (CAMN107A2103). * Extension protocol written informed consent. Exclusion criteria: * Inability to swallow the medication. * Any unresolved adverse events related to participation in the core protocol (CAMN107A2103). * A history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits. Other protocol defined inclusion/exclusion criteria may apply.